Trial Profile

A retrospective real world study to investigate the outcomes of patients with metastatic colorectal carcinoma treated with the bevacizumab and aflibercept sequence in real-world clinical practice-CORECT registry

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Antineoplastics; Capecitabine; Fluorouracil; Oxaliplatin
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Therapeutic Use

20 Feb 2020 New trial record
12 Feb 2020 Results (n=366; data cut-off: 30 April 2018) were published in the Targeted Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com